Mehmet Bilen, MD, Emory Winship Cancer Institute, Atlanta, GA, highlights novel approaches in evaluation for patients with kidney cancer, including immunotherapy-immunotherapy combinations, VEGF inhibitors, the onset of triplet therapies, as well as the anticipated use of HIF inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.
